Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2015

Filed with the SEC on Aug 12, 2015 and accepted by EDGAR at Aug 12, 2015, 17:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2015-04-01 to 2015-06-30$604.1kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2015-01-01 to 2015-06-30$925.5kus-gaap:ResearchAndDevelopmentExpense
Interest expense3 months2015-04-01 to 2015-06-30$0us-gaap:InterestExpense
Interest expense6 months2015-01-01 to 2015-06-30$1.9mus-gaap:InterestExpense
Net income3 months2015-04-01 to 2015-06-30−$1.5mus-gaap:ProfitLoss
Net income6 months2015-01-01 to 2015-06-30−$4.3mus-gaap:ProfitLoss
Diluted EPS3 months2015-04-01 to 2015-06-30−$0.24us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2015-01-01 to 2015-06-30−$2.57us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2015-01-01 to 2015-06-30−$2.7mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2015-06-30$1.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-06-30$1.4mus-gaap:AssetsCurrent
Total assetsAt period end2015-06-30$1.6mus-gaap:Assets
Current liabilitiesAt period end2015-06-30$642.6kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2015-06-30$913.7kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-15-048608. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.